Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

<p dir="ltr">Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of b...

Full description

Saved in:

Bibliographic Details
Main Author:	Shayista Akbar (14442117) (author)
Other Authors:	Afsheen Raza (492657) (author), Reyad Mohsin (14442120) (author), Aladdin Kanbour (14442123) (author), Shahnaz Qadri (2610634) (author), Aijaz Parray (290256) (author), Abdul Rehman Zar Gul (14777347) (author), Anite Philip (14442129) (author), Suma Vijayakumar (14442132) (author), Maysaloun Merhi (4246147) (author), Shereena Hydrose (14442135) (author), Varghese Philipose Inchakalody (14153292) (author), Rajaa Al-Abdulla (14442138) (author), Wafa Abualainin (14442141) (author), Shaza Abu Sirriya (18021691) (author), Issam Al-Bozom (4711098) (author), Shahab Uddin (154400) (author), Omar Muhammad Khan (14442147) (author), Mohamed Izham Mohamed Ibrahim (14158896) (author), Ussama Al Homsi (14442150) (author), Said Dermime (79420) (author)
Published:	2023
Subjects:	Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis exosomes NSCLC biomarkers immune-checkpoint inhibitors immune-oncological-checkpoints cytokines follow-up
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

Similar Items